Precision Toolbox
Integrated suite of translational, clinical, and computational tools for precision medicine in CNS diseases
Platform · OtherCompany source
Company profile
About Neumora
Neumora is a neuroscience-focused biopharmaceutical company pioneering precision medicine approaches for brain diseases. The company addresses a critical global health challenge affecting over 1.5 billion people worldwide who suffer from brain disorders with limited effective treatment options. Neumora takes a fundamentally different approach to developing treatments for Central Nervous System (CNS) diseases, moving beyond the single-class drug paradigm that has dominated conditions like Major Depressive Disorder (MDD). The company's pipeline comprises programs pursuing therapeutically relevant targets implicated in CNS diseases, each targeting a novel mechanism of action with best-in-class pharmacology. Neumora's work is supported by its proprietary Precision Toolbox, which integrates a suite of translational, clinical, and computational tools to generate insights that enable precision medicine approaches. The company has assembled a team of company builders, neuroscience drug developers, and data scientists committed to revolutionizing the treatment landscape for brain diseases. By applying the precision medicine revolution that has transformed oncology to neuroscience, Neumora aims to deliver targeted, effective medicines that address the significant unmet medical needs of patients with brain disorders.
Company description Neumora official website
Primary marketMental Health & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Neumora?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- brain diseases
- brain disorders
- Central Nervous System (CNS) diseases
- Major Depressive Disorder (MDD)
Who it serves
- Healthcare providers
- Patients
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsGlobal
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Neuronal α-Synuclein Disease Stage Progression over 5 Years.Movement disorders : official journal of the Movement Disorder Society · Jul 1, 2025
Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy.Cell reports · Jan 28, 2025
Biologically defined neuronal synuclein disease as a tool to advance drug development.NPJ Parkinson's disease · Dec 20, 2024
Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency.ACS chemical biology · Nov 15, 2024
Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse.Neuropharmacology · Oct 1, 2024
Analysis of gene expression in the postmortem brain of neurotypical Black Americans reveals contributions of genetic ancestry.Nature neuroscience · Jun 1, 2024
Clinical validation
Clinical-trial records
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013 · Sponsor · COMPLETED
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderNCT06058039 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Neumora
Recent articles published on Neumora's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Mental Health & Digital Therapeutics
Companies providing AI-powered mental health support, therapy platforms, mental wellness tracking, psychiatric care, digital therapeutics for mental health conditions, or AI-driven mental health screening and monitoring. Includes XR-based therapy, AI mental health screening infrastructure, and platforms supporting behavioral health for individuals and health systems.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.